The Influence of ACE Inhibition on C1-Inhibitor: A Biomarker for ACE Inhibitor-Induced Angioedema?
Angioedema
Angiotensin-converting enzyme inhibitor
Bradykinin
C1-inhibitor
Journal
Biomedicine hub
ISSN: 2296-6870
Titre abrégé: Biomed Hub
Pays: Switzerland
ID NLM: 101692630
Informations de publication
Date de publication:
Historique:
received:
21
01
2019
accepted:
03
02
2019
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
30
1
2020
Statut:
epublish
Résumé
Angioedema is a rare side effect of angiotensin-converting enzyme (ACE) inhibitors. It remains unclear why it is only induced in a few patients taking ACE inhibitors, often after a long period of uneventful treatment. The aim of this study was to analyze the influence of ACE inhibitor treatment on C1-inhibitor (C1-INH) levels. Captopril (5 mg/25 mg) was added to blood samples of 5 healthy subjects. C1-INH levels were measured before and after incubation for 180 min. The second section of the study was done with 17 patients who received therapy with an ACE inhibitor for the first time. C1-INH levels were measured before ACE inhibitor treatment, 24 h after first drug administration, and 4 weeks later. After incubation of blood samples with 5 mg captopril, there was no detectable change in C1-INH levels. After incubation with 25 mg, C1-INH activity was decreased by an average of 29% and the C1-INH concentration was decreased by an average of 0.06 g/L. In the second study section, inconsistent effects on C1-INH levels were detected. In the majority of patients, 24 h after the first ACE inhibitor administration C1-INH activity was tending to be increased. A dose-dependent effect on C1-INH levels in captopril-incubated blood samples of healthy test persons was shown. In patients with new ACE inhibitor treatment, heterogeneous reactions of C1-INH values were detected. Larger studies are needed over a longer period of time to find correlations between the effect of ACE inhibitor therapy on C1-INH levels and the clinical course/development of side effects.
Identifiants
pubmed: 31993426
doi: 10.1159/000499075
pii: bmh-0004-0001
pmc: PMC6985889
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-9Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
There are no competing interests to declare.
Références
J Pharm Pract. 2017 Dec;30(6):668-671
pubmed: 27837046
Cochrane Database Syst Rev. 2014 Aug 22;(8):CD009096
pubmed: 25148386
Immunotherapy. 2014;6(5):533-51
pubmed: 24635050
Proc Natl Acad Sci U S A. 1987 Sep;84(18):6374-8
pubmed: 2888113
J Gen Intern Med. 2012 Jun;27(6):716-29
pubmed: 22147122
Medicine (Baltimore). 2015 Nov;94(45):e1939
pubmed: 26559262
Nature. 1987 Jun 11-17;327(6122):524-6
pubmed: 3495737
ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):85-92
pubmed: 28231587
Proc Natl Acad Sci U S A. 1986 Feb;83(4):942-6
pubmed: 3081891
Methods Mol Biol. 2014;1100:189-205
pubmed: 24218261
Laryngoscope. 2015 Jun;125(6):E198-202
pubmed: 25583256
Mol Immunol. 2008 Oct;45(16):4057-63
pubmed: 18674818
N Engl J Med. 2015 Jan 29;372(5):418-25
pubmed: 25629740
J Clin Invest. 2002 Apr;109(8):1057-63
pubmed: 11956243
Pharmacol Rev. 2005 Mar;57(1):27-77
pubmed: 15734727
Br J Clin Pharmacol. 2005 Feb;59(2):233-8
pubmed: 15676047
Int J Emerg Med. 2017 Dec;10(1):15
pubmed: 28405953
Allergy. 2018 Aug;73(8):1575-1596
pubmed: 29318628
J Clin Hypertens (Greenwich). 2017 Dec;19(12):1377-1382
pubmed: 28994183
J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1402-1409.e3
pubmed: 28552382
J Clin Invest. 2015 Aug 3;125(8):3132-46
pubmed: 26193639
Am J Med. 1963 Jul;35:37-44
pubmed: 14046003
Arch Intern Med. 2005 Jul 25;165(14):1637-42
pubmed: 16043683
Clin Pharmacol Ther. 1996 Jul;60(1):8-13
pubmed: 8689816
BMJ Case Rep. 2015 Oct 23;2015:null
pubmed: 26498671
HNO. 2004 Oct;52(10):886-90
pubmed: 15592703
Am J Cardiol. 2012 Aug 1;110(3):383-91
pubmed: 22521308
Orphanet J Rare Dis. 2018 May 4;13(1):73
pubmed: 29728119
Thromb Haemost. 2010 Nov;104(5):886-93
pubmed: 20806108